Status:
TERMINATED
LESCOD: "Lewy Body Screening in Cognitive Disorders"
Lead Sponsor:
Nantes University Hospital
Conditions:
Alzheimer Disease
Lewy Body Disease
Eligibility:
All Genders
60-90 years
Phase:
NA
Brief Summary
Dementia with Lewy body (DLB) is the second most common neurodegenerative dementia in autopsy series. However, DLB represents a small proportion of the clinical diagnoses in epidemiology registries. I...
Eligibility Criteria
Inclusion
- Be a woman or a male \>60 to \< 90 years
- Have sufficient visual and auditory acuity
- Be able to speak, read, hear and understand french language
- Be covered by health care insurance
- Have a reliable help/partner/informant/caregiver
- Have a mild to severe cognitive decline based on MMSE (Mini-Mental State Examination) score ( From 18 to 26)
- Give oral agreement to the assessment of the LEsCoD scale during routine consultation
- Have performed neuropsychology tests and MRI respectively within 6 and 12 months
Exclusion
- Has evidence of neurological or psychiatric disorder other than AD or DLB explaining cognitive decline
- Has received previously or currently neuroleptic treatment
- Has no reliable help/caregiver the day of the visit
- Refuses to give his/her oral agreement to the assessment of the LeSCoD scale
- Has presence on MRI of radiologic evidence of cerebrovascular disease (score Fazekas 2)
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT02263287
Start Date
October 1 2014
End Date
August 1 2017
Last Update
December 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France